A bispecific monoclonal antibody T-cell engager designed to bind CLDN6 on tumor cells and engage T cells to kill CLDN6-positive cancer cells; administered intravenously or subcutaneously.
Bispecific antibody that binds CLDN6 on tumor cells and CD3 on T cells, recruiting and activating cytotoxic T lymphocytes to kill CLDN6-positive tumor cells; bivalent CLDN6 and monovalent CD3 binding enhances selective targeting.
NO
INDIRECT
XmAb541 binds CD3 on T cells to activate and recruit them to CLDN6+ tumor cells; the T cells then kill the CLDN6-expressing tumors (perforin/granzyme-mediated cytotoxicity). CD3+ cells themselves are not targeted for killing.
Intravenous type II anti-CD20 monoclonal antibody that targets CD20 on B cells to induce direct cell death and immune effector killing (ADCC/ADCP, some CDC).
Glycoengineered type II humanized IgG1 anti‑CD20 monoclonal antibody that binds CD20 on B cells and depletes them via enhanced FcγRIIIa‑mediated ADCC/ADCP and induction of direct, caspase‑independent cell death, with limited complement activation.
YES
DIRECT
Obinutuzumab binds CD20 on B cells, triggering type II, caspase‑independent direct cell death and engaging FcγRIIIa on NK cells/macrophages to mediate ADCC/ADCP (with limited CDC).
Intravenous type II anti-CD20 monoclonal antibody that targets CD20 on B cells to induce direct cell death and immune effector killing (ADCC/ADCP, some CDC).
Glycoengineered type II humanized IgG1 anti‑CD20 monoclonal antibody that binds CD20 on B cells and depletes them via enhanced FcγRIIIa‑mediated ADCC/ADCP and induction of direct, caspase‑independent cell death, with limited complement activation.
NO
INDIRECT
Obinutuzumab targets CD20 on B cells; its Fc binds FcγRIIIa (CD16a) on NK cells/monocytes to trigger ADCC/ADCP that kills CD20+ cells. CD16a-expressing effector cells are not targeted or killed by the drug.
Intravenous CD20×CD3 bispecific antibody that binds CD20 on lymphoma cells and CD3 on T cells, redirecting and activating T cells to kill B cells.
Glofitamab is a bispecific monoclonal antibody that simultaneously binds CD20 on B‑cell lymphoma cells and CD3 on T cells, crosslinking the two to redirect and activate T cells. This induces T‑cell activation and cytotoxicity against CD20‑expressing B cells, leading to targeted tumor cell lysis.
YES
DIRECT
By binding CD20 on target cells and CD3 on T cells, glofitamab redirects and activates T cells to form immune synapses and kill CD20+ cells via perforin/granzyme-mediated cytolysis and apoptosis.
Intravenous CD20×CD3 bispecific antibody that binds CD20 on lymphoma cells and CD3 on T cells, redirecting and activating T cells to kill B cells.
Glofitamab is a bispecific monoclonal antibody that simultaneously binds CD20 on B‑cell lymphoma cells and CD3 on T cells, crosslinking the two to redirect and activate T cells. This induces T‑cell activation and cytotoxicity against CD20‑expressing B cells, leading to targeted tumor cell lysis.
NO
INDIRECT
Glofitamab engages CD3 on T cells to activate them while binding CD20 on B cells; the activated T cells kill CD20+ B cells (perforin/granzyme), not the CD3+ T cells themselves.